Montelukast does help with asthma, and it has decades of clinical evidence behind it. It works differently from inhalers, targeting a specific inflammation pathway in the airways, and it’s taken as a daily pill rather than inhaled. That said, it’s generally not the first-choice treatment. Guidelines recommend it as an alternative to inhaled corticosteroids or as an add-on when inhalers alone aren’t enough.
How Montelukast Works
When you’re exposed to allergens, exercise, or other asthma triggers, your body releases chemicals called leukotrienes. These molecules cause the muscles around your airways to tighten, trigger swelling in the airway lining, and increase mucus production. Montelukast blocks the receptor where leukotrienes attach, preventing all three of those effects at once.
This is a fundamentally different approach from inhalers. Inhaled corticosteroids reduce inflammation broadly, and rescue inhalers relax airway muscles directly. Montelukast works upstream, stopping one of the key chemical signals that sets off the chain reaction in the first place. It begins working within about 2 hours of taking a tablet, reaches its peak effect in 3 to 4 hours, and lasts roughly 24 hours.
How Well It Controls Asthma Symptoms
In a study of 694 patients with asthma, allergic rhinitis, or both, about 64% of those with asthma showed sufficient improvement after four weeks on montelukast. Around 62% reported strong or marked improvement in daytime symptoms, and 60% reported the same for nighttime symptoms. Lung function measurements also improve: when montelukast is effective, the volume of air a person can forcefully exhale in one second (a standard measure of airway openness) typically increases by 15% to 35%.
These numbers make montelukast a solid option, but not the strongest one available. A Cochrane review of 13 randomized controlled trials concluded that low-dose inhaled corticosteroids are superior to montelukast for controlling persistent asthma. International treatment guidelines reflect this, recommending inhaled corticosteroids as the preferred first-line therapy and positioning montelukast as the recommended alternative.
Where Montelukast Fits in Treatment
According to the Global Initiative for Asthma guidelines, montelukast plays a role at multiple treatment steps. At the mildest level (step 2), it’s the go-to alternative if you can’t use or don’t tolerate inhaled corticosteroids. At more advanced levels (steps 3 and 4), it can be added on top of an inhaler-plus-long-acting-bronchodilator combination to improve control and potentially reduce the corticosteroid dose you need.
One important distinction: montelukast is a maintenance medication, not a rescue treatment. It reduces symptoms, lowers rescue inhaler use, and cuts down on flare-ups when taken consistently over time. It will not reverse an asthma attack that’s already happening. You still need a fast-acting rescue inhaler for that.
Exercise-Induced Asthma
Montelukast is particularly useful for people whose asthma is triggered by exercise. FDA review data from clinical trials showed that a single dose taken 2 hours before exercise significantly reduced the drop in lung function that occurs during exercise-induced bronchoconstriction, compared to placebo. Some patients were still protected at the 8.5-hour and even 24-hour marks after a single dose. One review found that montelukast protected against exercise-induced airway tightening better than long-acting bronchodilators.
The Allergy-Asthma Connection
If you have both asthma and seasonal allergies, montelukast can pull double duty. It’s FDA-approved for both conditions, and because leukotrienes drive nasal congestion and sneezing in addition to airway tightening, blocking them helps both problems at once. Research has shown that reducing allergy symptoms with montelukast also has a positive impact on asthma control in people dealing with both conditions. In the study of 694 patients mentioned earlier, about 70% of those with allergic rhinitis saw meaningful improvement in their nasal and eye symptoms alongside their asthma benefits.
Dosage and How to Take It
Montelukast is taken once daily in the evening for asthma. The dose depends on age:
- Adults and teens 15 and older: one 10 mg tablet
- Children 6 to 14: one 5 mg chewable tablet
- Children 2 to 5: one 4 mg chewable tablet or a packet of oral granules
Evening dosing is recommended because leukotriene levels tend to rise overnight, and timing the medication this way provides coverage during the hours when nighttime symptoms are most likely.
Side Effects and the FDA’s Boxed Warning
In clinical trials, montelukast’s physical side effects were mild and similar to placebo. The most commonly reported issues were upper respiratory infections, sore throat, fever, and (somewhat ironically) worsening asthma. These were reported at similar rates in both the montelukast and placebo groups.
The more serious concern involves mental health. In March 2020, the FDA added its strongest warning, a boxed warning, to montelukast’s label regarding neuropsychiatric side effects. The reported effects include agitation, aggression, depression, anxiety, vivid dreams, trouble sleeping, irritability, hallucinations, memory problems, restlessness, and suicidal thoughts. In clinical trials, behavior-related side effects occurred in about 2.7% of patients on montelukast versus 2.3% on placebo, a small absolute difference. But because post-marketing reports included serious events like suicidal thoughts and actions, the FDA took the extra step of restricting its recommended use for allergic rhinitis (reserving it for patients who don’t respond to other treatments) while keeping its asthma indication intact.
This doesn’t mean most people will experience mood changes, but it’s worth paying attention to how you or your child feels after starting the medication. The effects can appear at any point during treatment, not only in the first few days.
Who Benefits Most From Montelukast
Montelukast tends to work best in certain situations. People with both asthma and allergies often see the greatest benefit, since leukotrienes are heavily involved in allergic inflammation. It’s also a strong option for exercise-induced symptoms. Children who struggle with inhaler technique or who resist using inhalers consistently sometimes do better with a once-daily chewable tablet, and some studies in children found satisfaction and compliance were higher with montelukast than with inhaled corticosteroids, even when the clinical outcomes were similar.
On the other hand, people with more severe asthma or significantly reduced lung function generally need the stronger anti-inflammatory effect that corticosteroids provide. Montelukast alone is typically not enough in those cases, though it can still be useful as part of a broader treatment plan.